Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones

• Published in: Leukemia Vol. 17; no. 3; pp. 634 - 635
• Main Authors: CHEE, Y. L, VICKERS, M. A, STEVENSON, D, HOLYOAKE, T. L, CULLIGAN, D. J
• Format: Journal Article
• Language: English
• Published: London Nature Publishing 01.03.2003; Nature Publishing Group
• Subjects: Adult; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Benzamides; Biological and medical sciences; Clone Cells - pathology; Drug toxicity and drugs side effects treatment; Fatal Outcome; Humans; Imatinib; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology; Male; Medical sciences; Miscellaneous (drug allergy, mutagens, teratogens...); Myelodysplastic syndrome; Myelodysplastic Syndromes - chemically induced; Myelodysplastic Syndromes - pathology; Neoplasms, Second Primary - chemically induced; Neoplasms, Second Primary - pathology; Pharmacology. Drug treatments; Philadelphia Chromosome; Piperazines - adverse effects; Piperazines - therapeutic use; Pyrimidines - adverse effects; Pyrimidines - therapeutic use; Chromosomal aberration; Antineoplastic agent; Toxicity; Male; Myelodysplastic syndrome; Myeloproliferative syndrome; Chronic myelocytic leukemia; Genetics; Adult; Complication; Protein-tyrosine kinase; Chromosome translocation; Human; Imatinib; Enzyme; Transferases; Enzyme inhibitor; Malignant hemopathy; Philadelphia chromosome; Case study; Chemotherapy; Chronic; Treatment; Cytogenetics; Abnormal chromosome
• ISSN: 0887-6924; 1476-5381; 1476-5551
• DOI: 10.1038/sj.leu.2402842

Leukemia (2003) 17, 634-635. doi:10.1038/sj.leu.2402842